Halozyme Therapeutics, Inc. (LON:0J2O)

Market Cap	6.85B +19.6%
Revenue (ttm)	924.61M +31.2%
Net Income	443.01M +51.7%
EPS	3.52 +56.7%
Shares Out	n/a
PE Ratio	15.47
Forward PE	9.67
Dividend	n/a
Ex-Dividend Date	n/a

Volume	412
Average Volume	995
Open	82.46
Previous Close	80.09
Day's Range	77.11 - 82.46
52-Week Range	47.68 - 84.23
Beta	0.94
RSI	59.33
Earnings Date	Feb 17, 2026

About Halozyme Therapeutics

Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States and internationally. The company’s products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 that facilitates subcutaneous (SC) administration to enhance the disper...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 1998
• Employees: 350
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0J2O

Financial Performance

In 2024, Halozyme Therapeutics's revenue was $1.02 billion, an increase of 22.44% compared to the previous year's $829.25 million. Earnings were $444.09 million, an increase of 57.71%.

Financial numbers in USD